Vogelzang et al. conducted a study comparing the efficacy and safety of goserelin, a luteinizing hormone-releasing hormone (LHRH) agonist, with orchiectomy (surgical removal of the testes) in patients with Stage D2 prostate cancer. Here, GNRH1 is linked to prostate carcinoma.